ORIGINAL ARTICLE

Intravenous Wharton's Jelly stem cell increased the number of β cells pancreas and reduced the fasting blood glucose level in diabetes mellitus Wistar rat male (Rattus norvegicus)

Nadia Permatasari , Wimpie Pangkahila, Anak Agung Gde Budhiarta

Nadia Permatasari
Magister program of Biomedicine, Universitas Udayana, Denpasar. Email: [email protected]

Wimpie Pangkahila
Department of Andrology and Sexology, Faculty of Medicine, Universitas Udayana, Bali, Indonesia

Anak Agung Gde Budhiarta
Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Bali, Indonesia
Online First: April 24, 2021 | Cite this Article
Permatasari, N., Pangkahila, W., Budhiarta, A. 2021. Intravenous Wharton's Jelly stem cell increased the number of β cells pancreas and reduced the fasting blood glucose level in diabetes mellitus Wistar rat male (Rattus norvegicus). Bali Medical Journal 10(1): 160-163. DOI:10.15562/bmj.v10i1.2306


Introduction: Diabetes mellitus is a metabolic disease characterized by hyperglycemic and disorders of carbohydrate, protein and fat metabolism due to abnormalities in insulin secretion, insulin sensitivity or both. Based on previous research, Wharton's Jelly's mesenchymal stem cells have anti-inflammatory, immunoregulatory properties that can improve metabolic control and have the ability to differentiate into pancreatic lineage cells that function as insulin-producing cells in vitro culture. The purpose of this study was to prove that administration of mesenchymal stem cells Wharton's Jelly can increase the number of pancreatic beta cells and reduce fasting blood glucose levels in male rats (Rattus norvegicus) Wistar strain of diabetes mellitus.

Methods: The research design used was pure experimental with post-test only control group design using 36 white male rats. All samples were induced with Streptozotocin and Nicotinamide. The selected samples were divided into two groups: the control group given glibenclamide + 0.9% NaCl, and the treatment group was given glibenclamide + mesenchymal stem cells from Wharton's Jelly. Calculation of the number of pancreatic beta cells and measurement of blood glucose levels were carried out after 14 days of treatment.

Result: The results showed that the treatment group had a higher number of pancreatic beta cells than the control group (105.17 ± 16.379 cells/field of view vs. 54.00 ± 11.366 cells/field of view) (p <0.001). In addition, the treatment group had lower fasting blood glucose levels than the control group (109.06 ± 16.71 mg/dl vs 122.78 ± 10.14 mg / dl) (p <0.05).

Conclusion: It was concluded that intravenous administration of Wharton's Jelly mesenchymal stem cells increased the number of pancreatic beta cells and decreased fasting blood glucose levels in male rats (Rattus norvegicus) Wistar strain of diabetes mellitus.

References

Pangkahila W. Anti Aging Tetap Muda dan Sehat. PT Kompas Media Nusantara. 2011;

PERKENI. Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia [Internet]. Jakarta; 2011. Available from: www.perkeni.org

Preethi PJ. Herbal medicine for diabetes mellitus: A Review. Int J Phytopharm. 2013;3(1):1–22.

Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, et al. A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther. 2014;5(2):57. Available from: https://pubmed.ncbi.nlm.nih.gov/24759263

Ma L, Wang H, He H, Lin L, Li W, Huang T, et al. Human Umbilical Cord Wharton’s Jelly-Derived Mesenchymal Stem Cells Differentiate Into Insulin-Producing Cells. Blood. 2009;114(22):4578. Available from: http://dx.doi.org/10.1182/blood.v114.22.4578.4578

Quintiliano K, Bernardi L, Steffens D, Scher C, Fernandes T, Pranke P. Comparing two human umbilical cord mesenchymal stem cell isolation protocols. Universidade Federal do Rio Grande do Sul; 2010.

Wu XX, Shao JZ, Xiang C. Generation of pancreatic β cells from mesenchymal stem cells to treat type 1 diabetes. Stem Cells. 2014;2(1).

Anzalone R, Lo Iacono M, Loria T, Di Stefano A, Giannuzzi P, Farina F, et al. Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes. Stem Cell Rev Reports. 2010;7(2):342–63. Available from: http://dx.doi.org/10.1007/s12015-010-9196-4

Halim D, Murti H, Sandra F, Boediono A, Djuwantono T, Setiawan B. Stem Cell Dasar Teori & Aplikasi Klinis. 1st ed. Jakarta: Erlangga; 2010.

Kao S-Y, Shyu J-F, Wang H-S, Lin C-H, Su C-H, Chen T-H, et al. Comparisons of Differentiation Potential in Human Mesenchymal Stem Cells from Wharton’s Jelly, Bone Marrow, and Pancreatic Tissues. Stem Cells Int. 2015;2015:306158. Available from: https://pubmed.ncbi.nlm.nih.gov/26294917


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0